Welcome to NewPressRelease.com a free press release service. Publishing press releases for Public Relations never been easier. Just register (it's free and it takes less then a 1 minute) then use Submit Press Release. Our services aim to help you reach journalists and to improve visibility in search engine listings, so you can get the most publicity possible.

Elder Pharma Sets Sight on the Rs 800 Crore Nasal Inhaler Segment with Launch of "Solo" Inhalers

Lifestyle

(Free Press Release) * Plans Rural Push for expansion of its Health Care products through distribution expansion. * Lower price points and attractive packaging to boost company’s market share.

Elder Pharma Sets Sight on the Rs 800 Crore Nasal Inhaler Segment with Launch of "Solo" Inhalers


      

Mumbai, India, February 22nd, 2015 -- With a firm footing in the Health & Well Being segment, Elder Pharmaceuticals Limited (NSE ELDERPHARM) has expanded its Solo range of OTC products with the launch of Solo range of inhalers for nasal congestion. The Solo basket comprises of Solo Rub, a pain balm, Solo Cough Drops and Solo lozenges for throat soothening. With an eye on the rural markets, the company is also launching these products in smaller sizes and has earmarked a budget of Rs 25 crore for promotional activities.

Elder foresees an 8-10% annual growth in the nasal decongestion market and is banking on substantial growth from Category B & C Towns. The market is presently valued at Rs 800 crore with Vicks from P&G dominating with more than 50% market share. Market for inhalation generic drugs is quite promising for India due to climate change and rapidly aging demographics where 22% of population is above 55 years of age.  Although the market leaders are everywhere, there is still a large untapped market in India and Elder is hoping to garner a 7% share of the nasal decongestant market by FY2018.

Says Alok Saxena, Managing Director, Elder Pharmaceuticals Ltd, “Over the counter inhalers are the first level treatment for nasal congestion and doctors / specialists are consulted only if the condition worsens. Rising cost of raw materials, competitive market conditions and over dependency on the urban markets had affected the sales of the company’s OTC products in the recent years. With focus on Price, product mix and penetration, Elder is set to regain its prime position in the OTC sector.”

The market for Cough & Cold care solutions too witnessed a growth of 10% during 2013-14 due to increasingly erratic weather, whereby the temperature kept switching from hot and humid to cold and rainy, further increasing seasonal health problems such as, cough, cold and allergies. It is for this reason that the company has also introduced Solo lozenges in Polypack for better visibility and customer use. An ayurvedic Cough syrup which gives more than 12 hours of relief and has no side effects is also ready for launch in April 2015.

India's Fast Moving Health Goods (FMHG) sector has shown higher growth of 18% in Rural areas as compared to 11% in urban areas. Although, urban areas have high spending propensity, there has been a rise in disposable incomes levels in the rural economy and consequently in demand for FMHG products.

Add Saxena, “In view of the highly competitive nature of the industries we operate in, we plan to focus on branding, Packaging upgrades, wider distribution and innovation to make our brands successful. The company has also lined up marketing strategies to offer combination products for an attractive price in order to lure the rural consumers to try out it new launches.”

Press & Media Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876
Tel: (022) 28625131/32
Fax: (022) 28625133
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
http://www.publicrelationindia.com
http://www.elderindia.com

Share |



Elder Pharma Sets Sight on the Rs 800 Crore Nasal Inhaler Segment with Launch of "Solo" Inhalers

Source: Press Release

---------------------------

Disclaimer

If you have any questions regarding information in this press release, please contact the person listed as the Author or use the contact informations published in the press release. Please do not attempt to contact NewPressRelease.com. We are unable to assist you with any information regarding this release. NewPressRelease.com disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.

All press release information on this site, including free press releases, is solely based on what our users submit. NewPressRelease.com disclaims that any right and responsibility for the information goes to the user who submit the press release. Some press release may be confusing without additional explanation. You should contact the provider with any questions about the information presented. In case some press release damages your benefits or violate your rights in any way, please contact us and we'll remove it immediately.


Copyright © 2008 - 2014 Free Press Release by NewPressRelease.com